Bionano Genomics fully retires $20M secured convertible debentures, freeing itself from secured debt.

Bionano Genomics has fully retired and cancelled all $20 million of its outstanding Senior Secured Convertible Debentures originally issued in May 2024. This retirement completes the company's debt restructuring, releasing all liens on its assets and removing restrictive covenants. As a result, Bionano now carries no secured debt, gaining greater financial and operational flexibility to focus on growing its optical genome mapping business and executing its commercial strategy. The company plans to file additional details with the SEC soon.